TY - JOUR T1 - The mechanisms of antiinflammatory effect of mucolytic therapy JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P3612 AU - Usman Farkhutdinov AU - Valeriy Petryakov AU - Rafagat Farkhutdinov Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P3612.abstract N2 - Active oxygen forms (AOF) are of great importance in pathogenesis of lung inflammation. The efficacy of Ambroxol (A) in patients with lung diseases may be attributed to its potential influence on the production AOF by inflammatory cells.The aim was to study the efficacy of A in complex therapy of patients with COPD.Methods: The study included 52 patients with exacerbations of COPD. The production of AOF in the blood of patients was studied by registration of luminol dependent chemiluminescence (ChL). Bronchoalveolar lavage fluid (BALF) obtained during bronchofiberoscopy was examined for the determination of cell composition. The patients were divided into 2 groups. 25 patients with COPD received standard therapy (antibiotics, bronchodilators, glucocorticosteroids) and A inhalations. The other 27 patients received standard therapy and inhalations with placebo (sodium chloride solution).Results: ChL intensity of blood in patients with COPD exacerbations was found to be increased by 1.5 times. It indicated increased production of AOF by blood cells. In comparison to normal findings in BALF of patients the content of alveolar macrofages was reduced and the content of neutrofiles was high. The use of A in patients decreased generation of AOF in blood and the intensity of clinical symptoms, improved cellular composition of BALF. In the case of standard therapy high ChL intensity of blood and disorders in the cell composition of BALF were maintained, the duration of exacerbation period was longer.Conclusion: A administration in COPD exacerbations reduced AOF generation, improved the cell differential of BALF, increased the treatment efficiency. ER -